Latest / International Business with Fexingo: Global Trade, Cross-Border Deals, and Multinational Operations / How India Is Becoming the World's Generic Drug Factory
Transcript
- Lucas: You know that little orange bottle you pick up at the pharmacy — the one with your blood pressure meds or cholesterol statin — chances are that bottle was made in India. And not just a few — over forty percent of the generic prescriptions filled in the United States come from Indian manufacturers. Luna: That's a staggering number. And it's only getting bigger, right? I saw that India's generic drug exports hit something like twenty-five billion dollars last year. Lucas: Closer to twenty-seven billion, actually. And growing at about ten percent annually. Meanwhile, the US trade deficit in May widened to seventy-seven point six billion dollars — the biggest gap in over two years. A lot of that is the usual consumer goods and electronics, but pharma is becoming a surprisingly large slice. Luna: So we're essentially outsourcing our drug supply to India. And with the strong dollar — it's at one hundred twenty point five on the trade-weighted index — Indian drugs become even cheaper for US buyers. Lucas: Exactly. The dollar has been strong for a while — the yen is at one hundred sixty-two per dollar, the yuan is flat at six point seven eight — and that makes Indian exports even more competitive. If this episode was worth a coffee to you, you can support the show at buy me a coffee dot com slash fexingo. It keeps us ad-free and focused on what matters. Luna: Yeah, honestly, if you get value from these conversations, that small gesture goes a long way. And we're not going anywhere — but listener support helps us keep digging into these stories. Lucas: So back to India's pharma dominance. The key driver is cost. A generic drug made in India can cost sixty to eighty percent less than the same drug made in the US. That's because of lower wages, less stringent environmental regulations, and a massive pool of chemists and engineers. Luna: And that cost difference is only widening with the strong dollar. But there's a risk, too — if something disrupts that supply chain, we have a problem. Lucas: Right. And we've seen that play out in 2024 and 2025 when there were shortages of certain cancer drugs and antibiotics. The US Food and Drug Administration actually tracks over two hundred drugs that are in shortage at any given time — many of them generics from India. Luna: So what's driving this surge now? Is it just cheap labor, or are there other factors? Lucas: It's not just cost. India has also become incredibly efficient at getting drugs approved. The US FDA approved over a thousand generic drug applications last year — and more than half were from Indian companies. Sun Pharma, Dr. Reddy's, Aurobindo — they've built entire teams dedicated to navigating the FDA process. Luna: That's a competitive moat. It's not easy to replicate that institutional knowledge. Lucas: Exactly. And now there's talk of tariffs on generic drugs. The current administration has floated the idea of a twenty-five percent tariff on pharmaceutical imports — which would hit Indian generics directly. But here's the thing: even with a twenty-five percent tariff, Indian generics would still be cheaper than us made ones. Luna: So the tariff might not bring manufacturing back — it might just raise costs for patients. That's a tough political calculus. Lucas: Exactly. The Congressional Budget Office estimated that a twenty-five percent tariff on drugs could increase US healthcare costs by thirty to forty billion dollars a year. And it wouldn't necessarily create US jobs because the infrastructure isn't there. Luna: Speaking of infrastructure, there's also the quality control issue. We've seen recalls from Indian plants — some pretty big ones. Lucas: Yeah, that's the other side of the coin. The FDA has flagged manufacturing violations at several Indian plants. In 2025, they issued import alerts for two major facilities — one from Sun Pharma and one from Lupin. That can cause sudden shortages and price spikes. Luna: So it's a trade-off: lower cost but some supply risk. And with the strong dollar, the cost advantage is even more pronounced. Lucas: Let's put some numbers on it. India's share of the global generic drug market by volume is about fifteen percent. But by value, it's only about five percent — because the drugs are so cheap. That tells you how price-sensitive the market is. Luna: And that's not going to change anytime soon. Especially as patent cliffs loom — blockbuster drugs like Eliquis and Jardiance are going off patent in the next couple of years. Lucas: That's a huge opportunity for Indian companies. When a drug goes generic, the price can drop by eighty to ninety percent almost overnight. Indian manufacturers are already lining up to produce those. Luna: So what does this mean for the broader trade picture? The US trade deficit is already huge — seventy-seven point six billion in May. Adding more drug imports might widen it further. Lucas: But it's a different kind of deficit. Importing cheap drugs actually lowers healthcare costs for Americans. That's a net benefit. The problem is the optics — it looks like we're losing another industry. Luna: And that's why we see policy pushback. The Biden, Trump, and now the current administration have all talked about bringing pharma manufacturing back. But the economics just aren't there. Lucas: Not without massive subsidies. Building a US generic drug plant costs hundreds of millions, and the margins are razor-thin. Indian companies operate on margins of ten to fifteen percent — US companies would need double that to survive. Luna: So it's a classic case of comparative advantage. India has the chemists, the low cost base, and the regulatory know-how. The US has the market. Lucas: And that market is only going to grow. As the population ages, demand for generics will increase. The global generic drug market is projected to hit five hundred billion dollars by 2030 — up from about three hundred fifty billion today. Luna: And India is positioned to capture a big chunk of that growth. But there are risks — regulatory crackdowns, trade wars, maybe even a pandemic that disrupts supply. Lucas: Right. COVID showed us how fragile the supply chain can be. India itself imposed export restrictions on certain drugs during the crisis. That caused panic buying globally. Luna: So diversification is key. Some US companies are now looking at nearshoring to Mexico or even building plants in the US, but it's slow. Lucas: And expensive. The reality is that India's generic drug dominance isn't going away soon. It's a structural feature of the global economy now. Luna: So for investors, what's the play? Are Indian pharma stocks a buy? Lucas: They've had a good run. The Nifty Pharma index in India is up about twenty percent this year. But valuations are high — some companies trade at thirty times earnings. You have to be selective. Luna: And for patients? It means cheap drugs, but with occasional shortages. That's the trade-off. Lucas: I think the key takeaway is that global trade in pharmaceuticals is a double-edged sword. We get lower costs and more access, but we also take on supply chain risk. And policy interventions — like tariffs — could upset that balance. Luna: It's a reminder that trade isn't just about widgets and gadgets. It's about the medicine in your cabinet. Lucas: Exactly. And that's the story we'll keep following. For International Business with Fexingo, I'm Lucas. Luna: And I'm Luna. See you next time.